Icovamenib Achieves a Mean Reduction in HbA1c Greater than 1% at Week 26 Following 4 Weeks of Dosing in Type…
Novonesis will host a spotlight educational session on our Energy activities which is part of Planetary Health Biosolutions. We will…
LAS VEGAS, Nov. 18, 2024 (GLOBE NEWSWIRE) -- One World Products, Inc. (“OWP”) (OTCQB: OWPC), renowned for its innovative approach…
Company to highlight progress across its pipeline and showcase its path to reshaping the standard of care in I&I with…
INX-315, a potential best-in-class CDK2 inhibitor, to be evaluated in combination with Verzenio® (abemaciclib) and fulvestrant Combination therapy to be…
Promotes Edward Brennan, MD, FACS to Chief Scientific Officer & Head of R&D ProgramTORONTO and PHILADELPHIA, Nov. 18, 2024 (GLOBE…
Phase 2 CLOVER-WaM pivotal study data selected for oral presentation at 66th Annual American Society of Hematology Meeting and Exposition…
HCW Biologics entered into License, Research and Co-Development Agreement with WY Biotech for one of its new proprietary preclinical molecules…
OPUVIZ™ is one of the first wave aflibercept biosimilars in EuropeOPUVIZ is the second European Commission (EC)-approved ophthalmology biosimilar under…
The Company will now target five major cancer types with its four clinically active compounds across both TCR-T cell therapies…